Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002158 | 0.97 | SMN1; SMN2 (0.32) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL428515 | 0.73 | — | — | |
| SCHEMBL3092593 | 0.72 | — | — | |
| SCHEMBL428337 | 0.71 | ESR2 (0.38) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL529832 | 0.69 | CRBN (0.43) | SMN1; SMN2 | |
| SCHEMBL664740 | 0.69 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL4015148 | 0.69 | — | — | |
| SCHEMBL136340 | 0.67 | — | — | |
| SCHEMBL19255977 | 0.67 | CRBN (0.41) | SMN1; SMN2 | |
| SCHEMBL1177140 | 0.67 | SMN1; SMN2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | claimed |
| WO-1995023137-A1 | ACETIC ACID AMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 1995-08-31 | — | — | WO | claimed |
| US-5294619-A | N-(nitrogen-containing heterocyclylalkyl-phenyl-piperidines | PFIZER INC. (US) | 1994-03-15 | — | — | US | claimed |
| US-5250537-A | Treating psychoses | SCIOS NOVA INC. (US) | 1993-10-05 | — | — | US | claimed |
| WO-1990006303-A1 | ARYLPIPERIDINE DERIVATIVES | PFIZER INC. (US) | 1990-06-14 | — | — | WO | claimed |
| EP-0372776-A2 | Arylpiperidine derivatives | PFIZER INC. (US) | 1990-06-13 | — | — | EP | claimed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
| US-6608064-B2 | A pyrido(1,2-a)pyrazine compound | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20010034347-A1 | Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas | MCLEAN STAFFORD (US) | 2001-10-25 | — | — | US | disclosed |
| US-6300329-B1 | HETEROCYCLIC PYRIDO(1,2-A)PYRAZINE COMPOUNDS FOR TREATMENT OF PARKINSON'S DISEASE | PFIZER PRODUCTS INC. | 2001-10-09 | — | — | US | disclosed |
| EP-1115402-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS | Pfizer Products Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-1992000074-A2 | PYRIDOPYRAZINE DERIVATIVES FOR TREATING SUBSTANCE ABUSE AND ADDICTION | PFIZER INC. (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0395312-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
| EP-0380217-A1 | Bis-aza-bicyclic anxiolytic agents and antidepressants | PFIZER INC. (US) | 1990-08-01 | — | — | EP | disclosed |
| WO-1990008148-A1 | BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1990-07-26 | — | — | WO | disclosed |
| WO-1990008144-A1 | BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1990-07-26 | — | — | WO | disclosed |
| WO-1990006303-A1 | ARYLPIPERIDINE DERIVATIVES | PFIZER INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| EP-0372776-A2 | Arylpiperidine derivatives | PFIZER INC. (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034347-A1 | Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas | MAOB, MAOA, COMT | SMN1; SMN2 695/4885PIK3CD 201/4885PIK3CA 217/4885 |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | LIPE, LIPC, PNLIP | SMN1; SMN2 2519/4885PIK3CD 1887/4885PIK3CA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.